Treatment with RVD + stem cell transplant achieved higher PFS vs RV alone In patients with newly diagnosed multiple myeloma
In this MEDtalk Paul Richardson Dana Faber Cancer Institute, presents the data from the randomized phase 3 DETERMINATION trial in which patients with newly diagnosed multiple myeloma were randomly assigned to treatment with lenalidomide, bortezomib, and dexamethasone with and without an autologous stem cell transplant, with all receiving lenalidomide maintenance until progression.
